24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139] (Q24799644)

4 July 2017

title

24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139] (English)

1 reference

seasonal allergic rhinitis

4 July 2017

1 reference

1 reference

Luis M Salmun

1

Luis M

Salmun

1 reference

4 July 2017

Richard Lorber

series ordinal

2

author given names

Richard

author last names

Lorber

1 reference

4 July 2017

language of work or name

English

0 references

publication date

5 August 2002

1 reference

4 July 2017

1 reference

4 July 2017

volume

3

1 reference

4 July 2017

issue

1

0 references

page(s)

14

1 reference

A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects

4 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=122063

Desloratadine: A new, nonsedating, oral antihistamine

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=122063

28 September 2017

1 reference

https://api.crossref.org/works/10.1186%2F1471-2296-3-14

Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2296-3-14

Twenty-four hours of activity of cetirizine and fexofenadine in the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2296-3-14

Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2296-3-14

Oral bioavailability of desloratadine is unaffected by food

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2296-3-14

Desloratadine demonstrates dose proportionality in healthy adults after single doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2296-3-14

Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=122063

Nasal effect of cetirizine and loratadine at 24 hours in patients with allergic rhinitis.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=122063

28 November 2018

Identifiers

DOI

10.1186/1471-2296-3-14

1 reference

Dimensions Publication ID

4 July 2017

1019752590

0 references

Fatcat ID

release_dypddxr47vbq3kfqihwko47kfi

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dypddxr47vbq3kfqihwko47kfi

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMC publication ID

122063

1 reference

4 July 2017

1 reference